Health Technology Clinical Committee

Date: July 13, 2018
Time: 9:00 am – 10:00 am
Location: Webinar
Adopted:

Meeting materials and transcript are available on the HTA website

Draft HTCC Minutes

**Members present:** John Bramhall, MD, PhD, Gregory Brown, MD, PhD; Chris Hearne, RN, DNP, MPH; Laurie Mischley, ND, PhD, MPH; Carson Odegard, DC, MPH; Sheila Rege, MD MPH; Seth Schwartz, MD, MPH; Mika Sinanan, MD, PhD; Tony Yen, MD

**HTCC Formal Action**

1. **Call to order:** Dr. Brown, chair, called the meeting to order; members present constituted a quorum.

2. **May 18, 2018 meeting minutes:** Draft minutes reviewed; no changes or updates suggested. Dr. Rege motioned to approve May 18, 2018 minutes as written, Dr. Bramhall seconded. Committee voted to accept the minutes.

   **Action:** Nine committee members approved the May 18, 2018 meeting minutes.

3. **Surgery for lumbar radiculopathy/sciatica:** Chair referred members to the draft findings and determination and called for further discussion. The committee received no new information nor comments, no changes made to the draft.

   **Action:** One committee member abstained and eight voted to approve the Surgery for lumbar radiculopathy/sciatica findings and decision.

4. **Pharmacogenetic testing for patients being treated with oral anticoagulants:** Chair referred members to the draft finding and determination and called for further discussion. The committee received no new information nor comments, no changes made to the draft.

   **Action:** One committee member abstained and eight voted to approve the Pharmacogenetic testing for patients being treated with oral anticoagulants findings and decision.

**Chronic migraine and chronic tension-type headache:** The chronic migraine and chronic tension-type headache determination received final committee adoption on July 14, 2017. Comments received (June 20, 2017) from Dr. Shana Johnson (HCA) identified an inconsistency between determination language and original committee intent. The irregularity originates under HTCC Reimbursement Determination, Limitations of Coverage, OnabotulinumtoxinA injections must be discontinued when the condition--.
The committee reviewed Dr. Johnson’s comments regarding the reasons for discontinuation. The committee resolved the internal incongruity with intent by removing the second measure from the criteria under discontinuation.

Measure removed from the Limitations of Coverage:

(2) Has changed to episodic migraine (defined as <15 headache days per month) for three consecutive months.

**Action:** One committee member abstained and eight voted to approve the removal of the second criteria.

7. **HTA program updates:** Josh Morse, HTA program director, announced the hiring of a new Health Care Authority Medical Director.

8. **Meeting adjourned.**

**Health Technology Clinical Committee Authority:**

Washington State’s legislature believes it is important to use a science-based, clinician-centered approach for difficult and important health care benefit decisions. Pursuant to chapter 70.14 RCW, the legislature has directed the Washington State Health Care Authority (HCA), through its Health Technology Assessment (HTA) program, to engage in an evaluation process that gathers and assesses the quality of the latest medical evidence using a scientific research company and that takes public input at all stages.

Pursuant to RCW, 70.14.110 a Health Technology Clinical Committee (HTCC) composed of eleven independent health care professionals reviews all the information and renders a decision at an open public meeting. The Washington State HTCC determines how selected health technologies are covered by several state agencies (RCW 70.14.080-140). These technologies may include medical or surgical devices and procedures, medical equipment, and diagnostic tests. HTCC bases its decisions on evidence of the technology’s safety, efficacy, and cost effectiveness. Participating state agencies are required to comply with the decisions of the HTCC. HTCC decisions may be re-reviewed at the determination of the HCA Director.